🔎 Trials Near Me

Beranda › Kanker Saluran Empedu › California

Uji klinis Kanker Saluran Empedu di California

20 studi untuk Kanker Saluran Empedu mencari peserta di lokasi di California.

Kota di California

Teks studi resmi (Bahasa Inggris)

AZD0901 in Participants With Advanced Solid Tumours Expressing Claudin18.2

  • Research Site, Orange
  • Research Site, Palo Alto
  • Research Site, Santa Rosa
Menerima pesertaFase 2
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 30 Sep 2026 · NCT06219941

A Study to Select a Dose Regimen (Part A) and to Investigate Overall Survival (Part B) With Nanvuranlat Compared With Physician's Best Choice in Participants Aged 18 Years or Older With Biliary Tract Cancer

  • City of Hope (Site 107), Duarte
  • University of California at Irvine (Site 101), Orange
  • UCLA Medical Center (Site 117), Santa Monica
Menerima pesertaFase 3
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 29 Sep 2026 · NCT07265674

Spevatamig (PT886) as Monotherapy or in Combination With Chemo and/or Targeted Therapy and/or ICI, for the Treatment of Patients With Advanced Gastrointestinal Cancers, Including Gastric, Gastroesophageal Junction, Pancreatic Ductal or Biliary Tract Carcinomas (the TWINPEAK Study)

  • City of Hope (City of Hope National Medical Center, City of Hope Medical Center), Duarte
  • USC Norris Comprehensive Cancer Center, Los Angeles
Menerima pesertaFase 1/2
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 28 Sep 2026 · NCT05482893

A Study of Rilvegostomig or Durvalumab Plus Chemotherapy for First-Line Treatment of Biliary Tract Cancer (ARTEMIDE-Biliary02)

  • Research Site, Duarte
  • Research Site, Los Angeles
  • Research Site, Orange
  • dan 1 lainnya
Menerima pesertaFase 3
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 28 Sep 2026 · NCT07221253

A Clinical Study of MK-2870 Alone or With Other Treatments to Treat Gastrointestinal Cancers (MK-9999-02A)

  • UCLA ( Site 0317), Los Angeles
Menerima pesertaFase 1/2
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 25 Sep 2026 · NCT06428409

Study of Dato-DXd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03)

  • Research Site, Los Angeles
  • Research Site, Santa Rosa
Menerima pesertaFase 2
Usia 18 hingga 130 · Semua jenis kelamin · Diperbarui 23 Sep 2026 · NCT05489211

Open Label Study to Evaluate BL-M07D1 in HER2 Expressing Malignant Solid Tumors

  • City of Hope, Duarte
  • START - Los Angeles, Los Angeles
  • Cedars Sinai, Los Angeles
  • dan 1 lainnya
Menerima pesertaFase 1
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 10 Sep 2026 · NCT06293898

AVENTINE-1: Study of AVZO-1418 as a Single Agent and in Combination Therapy in Patients With Locally Advanced or Metastatic Solid Tumors (AVZO-1418-1001)

  • Avenzo Therapeutics Recruiting Site, Los Angeles
  • Avenzo Therapeutics Recruiting Site, Los Angeles
Menerima pesertaFase 1/2
Usia 18 hingga 75 · Semua jenis kelamin · Diperbarui 4 Sep 2026 · NCT07038343

A Phase 1 Study of LNCB74 in Advanced Solid Tumors

  • Hoag Family Cancer Institute, Newport Beach
Menerima pesertaFase 1
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 21 Agu 2026 · NCT06774963

Phase 3 Study of T-DXd and Rilvegostomig Versus SoC in Advanced HER2-expressing Biliary Tract Cancer

  • Research Site, Fullerton
  • Research Site, La Jolla
  • Research Site, Los Angeles
  • dan 3 lainnya
Menerima pesertaFase 3
Usia 18 hingga 99 · Semua jenis kelamin · Diperbarui 19 Agu 2026 · NCT06467357

A Study to Evaluate the Efficacy and Safety of Ifinatamab Deruxtecan (I-DXd) in Subjects With Recurrent or Metastatic Solid Tumors (IDeate-PanTumor02)

  • Los Angeles Cancer Network, Los Angeles
  • Pih Health Hematology Medical Oncology, Whittier
Menerima pesertaFase 1/2
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 5 Agu 2026 · NCT06330064

A Study to Assess the Efficacy and Safety of FORE8394 in Participants With Cancer Harboring BRAF Alterations

  • Precision NextGen Oncology & Research Center, Beverly Hills
  • UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco
  • University of California Los Angeles Rheumatology, Westwood, Los Angeles
Menerima pesertaFase 2
Usia 8 ke atas · Semua jenis kelamin · Diperbarui 27 Jul 2026 · NCT05503797

Locally ablatIVe thErapy for oLigo-progressive gastrOintestiNal maliGnancies (LIVELONG)

  • University of California, Davis Comprehensive Cancer Center, Sacramento
Menerima peserta
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 2 Jul 2026 · NCT06101277

A Phase 1 Dose-escalation Trial of KST-6051 in Participants With Advanced Solid Tumors With Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Mutation

  • Cedars-Sinai Medical Center, Los Angeles
Menerima pesertaFase 1
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 29 Jun 2026 · NCT07458347

A Phase 1/1B Study of ST-01156, a Small Molecule RBM39 Degrader, in Patients With Advanced Solid Malignancies

  • The City of Hope National Medical Center, Duarte
  • Hoag Memorial Hospital, Newport Beach
Menerima pesertaFase 1
Usia 16 ke atas · Semua jenis kelamin · Diperbarui 2 Jun 2026 · NCT07197554

Study of RP2 in Combination With Second-line Therapy in Patients With Locally Advanced or Metastatic HCC

  • Beverly Hills Cancer Center, Beverly Hills
  • UC San Diego Moores Cancer Center, La Jolla
Menerima pesertaFase 2
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 2 Apr 2026 · NCT05733598

Study of TJ033721 (Givastomig) in Subjects With Advanced or Metastatic Solid Tumors

  • Stern Center for Cancer Clinical Trials and Research, Orange
Menerima pesertaFase 1
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 5 Mar 2026 · NCT04900818

Virtual Reality for GI Cancer Pain to Improve Patient Reported Outcomes

  • Cedars-Sinai Medical Center, Los Angeles
Menerima peserta
Usia 18 hingga 99 · Semua jenis kelamin · Diperbarui 20 Feb 2026 · NCT04907643

A Study of MT-4561 in Patients With Various Advanced Solid Tumors

  • University of Southern California, Los Angeles
Menerima pesertaFase 1/2
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 11 Des 2025 · NCT06943521

Dari ClinicalTrials.gov, data diambil 5 Okt 2026. Setiap studi menetapkan kriteria kelayakannya sendiri; tim studi yang menentukan siapa yang bisa bergabung.